Poster Sessions

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Friday, January 18, 2019 11:30 AM-1:00 PM and 5:30 PM-6:30 PM

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Friday, January 18, 2019 11:30 AM-1:00 PM and 5:30 PM-6:30 PM

Posters by Topic
Prevention, Diagnosis, and Screening: Poster Boards A9-D3
Multidisciplinary Treatment: Poster Boards A1-A6, A8, F15-P17
Translational Research: Poster Boards A7, D4-F14
Trials in Progress: Poster Boards P19-Q18

BOARD A1
Abstract 189: Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
First Author: Michiaki Unno, MD, PhD


BOARD A2
Abstract 186: Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).
First Author: Masatoshi Kudo, MD, PhD


BOARD A3
Abstract 187: Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial.
First Author: Zev Wainberg, MD


BOARD A4
Abstract 188: Integrative molecular profiling and response to chemotherapy on the COMPASS trial.
First Author: Grainne O'Kane


BOARD A5
Abstract 185: Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
First Author: Ahmed Kaseb, MD


BOARD A6
Abstract 190: Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.
First Author: Jonathan Strosberg, MD


BOARD A7
Abstract 191: Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program.
First Author: Michael Pishvaian, MD, PhD


BOARD A8
Abstract 192: Immune checkpoint inhibition (ICI) in combination with SBRT in patients with advanced pancreatic adenocarcinoma (aPDAC).
First Author: Gagandeep Brar, MD


BOARD A9
Abstract 193: Distribution of insulin growth factor-1 (IGF-1) binding proteins in hepatocellular carcinoma with and without cirrhosis.
First Author: Ahmed Abdelhakeem, M.D


BOARD A10
Abstract 194: Peritoneal carcinomatosis (PC) in well-differentiated (WD) small-intestinal neuroendocrine tumor (SI-NET) patients (Pts) with mesenteric tumor deposits (MTDs).
First Author: Satya Das, MD


BOARD A11
Abstract 195: Determination of O-6-methylguanine-DNA methyltransferase by immunochemistry and pyrosequencing as a predictive factor of response to temozolomide in pancreatic neuroendocrine tumors.
First Author: Roberto Escala


BOARD A12
Abstract 196: The clinical implication of CD45RA+ naive T cells and CD45RO+ memory T cells in advanced pancreatic cancer: A proxy for tumor biology and outcome prediction.
First Author: Junjie Hang, M.D.


BOARD A13
Abstract 197: Development of a nomogram to predict overall survival in patients presenting with gastrointestinal neuroendocrine carcinoma (WHO G3).
First Author: Zhenyu Lin, MD


BOARD A14
Abstract 198: Baseline and longitudinal quantification of lean muscle mass using routine CT measurements prior to resection for pancreatic adenocarcinoma.
First Author: Paul Oberstein, MD


BOARD A15
Abstract 199: Predictive factors for major complications after pancreaticoduodenectomy in patients aged 80 years or older.
First Author: Naoya Takeda, MD


BOARD A16
Abstract 200: Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage.
First Author: Marcus Noel, MD


BOARD A17
Abstract 201: Hepatocellular carcinoma (HCC) survival by etiology: A SEER-Medicare database analysis.
First Author: Gagandeep Brar, MD


BOARD A18
Abstract 202: Meta-analysis of OS for pancreatic cancer patients receiving 5FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy.
First Author: Zev Wainberg, MD


BOARD A19
Abstract 203: CA19-9 decrease and overall survival according to platelet level in patients with metastatic pancreatic cancer.
First Author: Yang Chen, M.D., Ph.D


BOARD A20
Abstract 204: Suggestion of new nomogram including inflammatory marker for predicting invasive carcinoma in intraductal papillary mucinous neoplasm of the pancreas.
First Author: In Woong Han, MD, PhD


BOARD B1
Abstract 205: Role of central hypovascularity in the hepatic arterial phase of dynamic CT on mass-forming intrahepatic cholangiocarcinoma.
First Author: Mitsuo Shimada, MD, PhD


BOARD B2
Abstract 206: The evaluation of the eighth edition of the AJCC/UICC staging system for intrahepatic cholangiocarcinoma: A proposal of a modified new staging system.
First Author: Yusuke Yamamoto, M.D., Ph.D.


BOARD B3
Abstract 207: Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.
First Author: Ghassan Abou-Alfa, MBA, MD


BOARD B4
Abstract 208: Investigating disparities: The effect of social environment on pancreatic cancer survival.
First Author: David Madnick, None


BOARD B5
Abstract 209: Measurement of urinary kininogen (KNG) fragments as a noninvasive tool for early diagnosis of pancreatic cancer (PaCa).
First Author: Izumi Ohno, MD, PhD


BOARD B6
Abstract 210: Prevalence of pancreaticobiliary cancer in Irish families with BRCA1 and BRCA2 mutations.
First Author: Robert Power, None


BOARD B7
Abstract 211: Multiplatform profiling of pancreatic neuroendocrine tumors (PanNETs) identifies novel co-occurring pathogenic alterations and associations with clinicopathologic factors.
First Author: Michelle Guan, BS


BOARD B8
Abstract 212: Preoperative evaluation with computed tomography (CT) of the resectability of mesenteric lymph node metastases in small intestine neuroendocrine neoplasms (si-NENs): New criteria for clinicians and surgeons.
First Author: Luigi Funicelli, MD


BOARD B9
Abstract 213: The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.
First Author: Sang Eun Yoon


BOARD B10
Abstract 214: Early detection of pancreatic ductal adenocarcinoma using abnormal urinary fragmentation ratio of a liver-originated protein.
First Author: Motoyasu Kan


BOARD B11
Abstract 215: Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.
First Author: Navika Shukla


BOARD B12
Abstract 216: Enhancements in pancreatic protocol CT as a prognostic indicator in pancreatic cancer.
First Author: Jaewon Park, MD


BOARD B13
Abstract 217: Comparison of biomarkers among 34855 GI cancer samples shows heterogeneity of tumor types.
First Author: Shaheenah Dawood, FACP, FRCP


BOARD B14
Abstract 218: Circulating calprotectin, innate inflammatory protein, was decreased under disease control during first line chemotherapy for advanced pancreatic cancer.
First Author: Taro Shibuki


BOARD B15
Abstract 219: Prognostic significance of nutritional and inflammatory markers in patients with unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.
First Author: Ryosuke Kobiyama


BOARD B16
Abstract 220: Clinical outcome of pancreatic cancer patients with indeterminate pulmonary nodules.
First Author: Austin Kazarian, BS


BOARD B17
Abstract 221: Impact of the distance from the root of the splenic artery to the tumor in patents with the pancreatic body/tail cancer.
First Author: Takuya Minagawa, M.D.


BOARD B18
Abstract 222: Sensitivity and specificity of the NETest: A validation study.
First Author: Taymeyah Al-Toubah, MPH


BOARD B19
Abstract 223: IGF-Child-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy.
First Author: Yehia Abugabal, MD


BOARD B20
Abstract 224: Role of nonalcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its role in patients’ prognosis: A case-control study.
First Author: Stefania De Lorenzo, MD


BOARD C1
Abstract 225: Incidence and trends of pancreatic cancer (PC) in Girona: A population-based study from the Girona Cancer Registry (1994-2015).
First Author: Adelaida Garcia-Velasco, MD


BOARD C2
Abstract 226: Designing clinical trials in 3L+ pancreatic cancer.
First Author: Victoria Manax, MD


BOARD C3
Abstract 227: Plasma GH as a diagnostic and prognostic biomarker in HCC without cirrhosis.
First Author: Roberto Carmagnani Pestana, MD


BOARD C4
Abstract 228: Validity of hepatic cone-unit resection for hepatocellular carcinoma.
First Author: Satoru Imura, MD, PhD


BOARD C5
Abstract 229: Differences in presentation and management patterns in patients with hepatocellular carcinoma (HCC): Data from HCC registry in Asia.
First Author: Pierce Chow, MBBS, FRCS, PhD


BOARD C6
Abstract 230: Immunotherapy response evaluation with MR elastography (MRE) in advanced HCC.
First Author: Aliya Qayyum, MD


BOARD C7
Abstract 231: Epidemiology and characteristics of patients (pts) with hepatocellular carcinoma (HCC) and care in the United States.
First Author: Yunes Doleh, PharmD, MPH


BOARD C8
Abstract 232: VTE among pancreatic cancer and its possible risk factors among metastatic pancreatic cancer (mPC): Experience at Fox Chase Cancer Center.
First Author: Ramesh Pandey, MD


BOARD C9
Abstract 233: Circulating tumor DNA may correlate with tumor size changes following therapy.
First Author: John Chang, M.D., Ph.D.


BOARD C10
Abstract 234: A blood-based assay for diagnosis of early-stage pancreatic cancer.
First Author: Thomas Ettrich, MD


BOARD C11
Abstract 235: Factors associated with biopsy diagnosis of hepatocellular carcinoma.
First Author: Young soo Rho


BOARD C12
Abstract 236: Landscape of germline mutations in hepatobiliary carcinoma: Unrealized risk, untapped clinical trial opportunities.
First Author: Jewel Samadder, MD, MSc


BOARD C13
Abstract 237: The spectrum of activating EGFR mutations from cell-free DNA (cfDNA) in large pancreatic cancer cohort.
First Author: Kristin Price, MS


BOARD C14
Abstract 238: Impact of Ga-68 DOTATATE imaging on clinical management of neuroendocrine tumor patients: Post-FDA-approval analysis of first 200 clinical patients.
First Author: Aman Chauhan, MBBS


BOARD C15
Abstract 239: Leptomeningeal carcinomatosis in BRCA-mutated pancreatic cancer.
First Author: Jessica Slostad, M.D.


BOARD C16
Abstract 240: Insurance status and hepatocellular carcinoma: A NCDB analysis.
First Author: Hibah Ahmed, B.S.


BOARD C17
Abstract 241: High-income is a stronger predictor than race in understanding disparate survival outcomes in PDAC.
First Author: Marcus Alvarez, MD


BOARD C18
Abstract 242: Incidence patterns of neuroendocrine neoplasms in California.
First Author: Alan Paciorek, BS


BOARD D1
Abstract 243: Aspirin and statin use and the risk of gallbladder cancer.
First Author: Kritika Prasai, M.B.B.S


BOARD D2
Abstract 244: Sorafenib versus transarterial chemoembolization as adjuvant therapies for patients with hepatocellular carcinoma and microvascular invasion.
First Author: Xinyu Bi


BOARD D3
Abstract 245: Epidemiological trends of small bowel tumors and changing incidence in Utah.
First Author: Ramya Thota, MBBS


BOARD D4
Abstract 246: Dissecting the spatial heterogeneity of single circulating tumor cells reveals immune evasion through MAX regulated CCL5 overexpression in hepatocellular carcinoma.
First Author: Yun-Fan Sun, MD, PhD


BOARD D5
Abstract 247: A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.
First Author: Maxine Kish, MSc


BOARD D6
Abstract 248: Soluble urokinase plasminogen activator receptor (suPAR) as a novel biomarker in patients undergoing resection of pancreatic adenocarcinoma.
First Author: Sven Loosen


BOARD D7
Abstract 249: A phase Ib dose escalation study of vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer.
First Author: S. Davis, MD


BOARD D8
Abstract 250: Using novel real-time tracking to monitor postoperative recovery in a comprehensive cancer center.
First Author: Sharlene Dong, BS


BOARD D9
Abstract 251: Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer.
First Author: Alexander Lim, MD


BOARD D10
Abstract 252: Imaging findings of patients undergoing SBRT for HCC after prior TACE.
First Author: Aneliya Maleeva, MD


BOARD D11
Abstract 253: Enhancement of the efficacy of radiofrequency ablation by neoadjuvant oncolytic virus therapy via antitumor immunity and the booster effect of immune checkpoint inhibitors.
First Author: Tomoharu Yamada, M.D.


BOARD D12
Abstract 254: Clinical significance of monitoring KRAS in tissue and plasma of pancreatic cancer patients.
First Author: Fumiaki Watanabe


BOARD D13
Abstract 255: Sunitinib in patients with pancreatic neuroendocrine tumors (panNETs): Exploratory pharmacogenomic analyses.
First Author: Nicola Fazio, MD, PhD


BOARD D14
Abstract 256: Growth factor signaling in pancreatic neuroendocrine tumor metastases.
First Author: Brenna Rheinheimer, PhD


BOARD D15
Abstract 257: The prognostic role of soluble transforming growth factor-β (sTGFb) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine.
First Author: Jin Won Kim, MD, PhD


BOARD D16
Abstract 258: Investigation of aberrant DNA methylation in association with cisplatin-resistant hepatoblastoma.
First Author: Sunao Fujiyoshi, MD


BOARD D17
Abstract 259: Gastrin vaccine and immune checkpoint antibody therapy for pancreatic cancer.
First Author: Jill Smith, MD


BOARD D18
Abstract 260: Whole-exome sequencing in unresectable pancreatic cancer patients with long-term survival.
First Author: Kentaro Sudo, MD, PhD


BOARD D19
Abstract 261: Circulating free tumor DNA copy number index (CNI) as a predictor of therapeutic response in pancreatic ductal adenocarcinomas (PDAC).
First Author: Madappa Kundranda, MD, PhD, FACP


BOARD D20
Abstract 262: Burden of carcinoid heart disease in patients initiating treatment for carcinoid syndrome.
First Author: Vijay Joish, PhD


BOARD E2
Abstract 264: Randomized phase II trial of the carboxylesterase (CES)-converted novel drug EDO-S7.1 in patients (pts) with advanced biliary tract cancers (BTC).
First Author: Ulrich-Frank Pape, MD


BOARD E3
Abstract 265: The effect of hepatic stellate cells on hepatocellular carcinoma progression.
First Author: Shuichi Iwahashi, MD, PhD


BOARD E4
Abstract 266: Deleterious alterations in DNA-damage repair (daDDR) genes as a predictive biomarker for platinum-based chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Sofia Palacio, MD


BOARD E5
Abstract 267: The impact of the immune microenvironment in patients with GEP-NETs.
First Author: Marina Baretti, MD


BOARD E6
Abstract 268: An open-label phase Ib/2 trial of TRC105 plus sorafenib in patients with advanced/metastatic hepatocellular carcinoma (HCC) (NCT01806064).
First Author: Kanwal Raghav, MD, MBBS


BOARD E7
Abstract 269: Mutational landscape by targeted next-generation sequencing in EBV-associated lymphoepithelioma-like cholangiocarcinoma.
First Author: Nai-Jung Chiang, MD


BOARD E8
Abstract 270: A pilot study of galunisertib (LY2157299 monohydrate) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC).
First Author: Kim Reiss, MD


BOARD E9
Abstract 271: Comprehensive characterization of single circulating rare cells through automated picking and high-throughput mRNA profiling in patients with pancreatic cancer.
First Author: Dong Uk Kim


BOARD E10
Abstract 272: Thermal safety and effectiveness of tumor treating fields’ delivery to the abdomen as determined by computational simulations.
First Author: Uri Weinberg, MD


BOARD E11
Abstract 273: Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.
First Author: Michael Lee, FRACP, MBChB


BOARD E12
Abstract 274: The feasibility of hepatectomy for the super-elderly patients with HCC.
First Author: Shogo Ohta


BOARD E13
Abstract 275: Patient reported abdominal pain as a surrogate of the clinical benefit of tipifarnib in pancreatic cancer patients.
First Author: Antonio Gualberto, MD, PhD


BOARD E14
Abstract 276: KRAS and TP53 status as a predictor of survival in patients with resected pancreatic ductal adenocarcinoma.
First Author: Caitlin McIntyre, MD


BOARD E15
Abstract 277: Phase II pharmacokinetics of oral SM-88 in heavily pretreated advanced pancreatic ductal adenocarcinoma (PC).
First Author: Marcus Noel, MD


BOARD E16
Abstract 278: The impact of CDKN2A mutations on overall survival in pancreatic adenocarcinoma.
First Author: Allison Doyle, MPH


BOARD E18
Abstract 280: A multi-institutional study assessing prevalence of deleterious germline mutations in pancreatic cancer.
First Author: Meena Sadaps, MD


BOARD E19
Abstract 281: Frequency and feasibility of detecting FGFR mRNA expression in archival samples of patients with cholangiocarcinoma (CCA).
First Author: Abhijit Chougule, PhD


BOARD E20
Abstract 282: Comprehensive genomic profiling in metastatic pancreatic adenocarcinoma, correlation with early death versus prolonged survival.
First Author: Mandana Kamgar, MD, MPH


BOARD F1
Abstract 283: Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results from a dose escalation.
First Author: Carlos Becerra, MD


BOARD F2
Abstract 284: Sequential gemcitabine (G), oxaliplatin (O), and irinotecan (I) based weekly metronomic chemotherapy (MC) regimens for the treatment of metastatic pancreatic cancer (mPC): A community cancer clinic experience.
First Author: Ben Chue, MD


BOARD F3
Abstract 285: Defining DNA damage repair deficiency and replication stress in pancreatic cancer.
First Author: Stephan Dreyer


BOARD F4
Abstract 286: MAPK pathway proteins expression and correlation with clinicopathological indices and long-term outcome according to the etiology of underlying chronic liver disease in hepatocellular carcinoma.
First Author: Paulo Diniz, MD


BOARD F5
Abstract 287: Clinical trial screening of CDKN2A genomic alterations in patients with pancreatic cancer and hepatobiliary cancers requires greater precision than somatic sequencing alone.
First Author: Charles Vaske, PhD, BS


BOARD F6
Abstract 288: Impact of obesity upon the survival of cholangiocarcinoma patients.
First Author: Phani Keerthi Surapaneni, MBBS


BOARD F7
Abstract 289: Landscape of circulating tumor DNA profiling of advanced pancreatic cancer (PDAC).
First Author: Kabir Mody, MD


BOARD F8
Abstract 290: Measuring liver radioembolization dose with positron emission tomography.
First Author: Vladimir Avkshtol


BOARD F9
Abstract 291: Landscape of circulating tumor DNA and tissue-based profiling in advanced cholangiocarcinoma.
First Author: Kabir Mody, MD


BOARD F10
Abstract 292: Transcript profiling of neuroendocrine tumors (NETs) to identify new targets and mechanism of progression.
First Author: Emily Walzer, MD


BOARD F11
Abstract 293: Inhibition of diacylglycerol kinase alpha to augment antitumor effector T cells in tumor-bearing host.
First Author: Naoki Okada, MD


BOARD F12
Abstract 294: Pilot study of plasma KRAS as a prognostic biomarker in localized pancreas ductal adenocarcinoma (PDAC).
First Author: Benjamin Krantz, MD


BOARD F13
Abstract 295: Characterization of the tumor mutation burden in hepatobiliary tumors.
First Author: Ramya Thota, MBBS


BOARD F14
Abstract 296: Novel prognostic biomarkers and their association with survival in pancreatic cancers.
First Author: Anup Kasi, MD, MPH


BOARD F15
Abstract 297: Symptom burden at the end of life for neuroendocrine tumors: A population-based analysis of patient-reported outcomes.
First Author: Julie Hallet, MD


BOARD F16
Abstract 298: Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC).
First Author: Zev Wainberg, MD


BOARD F17
Abstract 299: Outcomes of patients with borderline-resectable pancreatic cancer treated with FOLFIRINOX versus gemcitabine plus nab-paclitaxel.
First Author: Shaina Templeton, BSc


BOARD F18
Abstract 300: Line of therapy (LOT) definition impacts second-line (2L) survival duration in a metastatic pancreatic cancer (mPCa) electronic health record database.
First Author: Susan Fish, MS


BOARD F19
Abstract 301: Impact of renal function on the efficacy and safety of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
First Author: Satoshi Kobayashi, MD


BOARD F20
Abstract 302: Clinical impact of preoperative biliary drainage on postoperataive complications in pancreaticoduodenectomy.
First Author: Hirohisa Okabe, MD, PhD


BOARD G1
Abstract 303: Real-world outcomes among patients (pts) treated with gemcitabine (GEM)-based therapy post-FOLFIRINOX (FFOX) failure in advanced pancreatic cancer (APC).
First Author: Erica Tsang, MD


BOARD G2
Abstract 304: Biliary tract cancers and the associated risk of venous thromboembolism.
First Author: Jasleen Khanuja, MD


BOARD G3
Abstract 305: Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including hepatocellular carcinoma (HCC).
First Author: Linh Nguyen, PhD


BOARD G4
Abstract 306: A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.
First Author: Masafumi Ikeda, MD


BOARD G5
Abstract 307: A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer.
First Author: Christine Alewine, MD, PhD


BOARD G6
Abstract 308: Adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunostaining in curative resected pancreatic adenocarcinoma: A biomaker stratified trial.
First Author: Dong Woo Shin, BS


BOARD G7
Abstract 309: Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliative and functional outcomes—Final results of a prospective clinical trial.
First Author: Yaacov Lawrence, MA, MBBS, MRCP


BOARD G8
Abstract 310: Feasibility of SM-88 in PC after multiple prior lines and ECOG < 2 (NCT03512756).
First Author: Marcus Noel, MD


BOARD G9
Abstract 311: Predictive role of temporal changes in intratumoral metabolic heterogeneity during palliative chemotherapy in advanced pancreatic cancer patients: A prospective cohort study.
First Author: Shin Hye Yoo


BOARD G10
Abstract 312: Neoadjuvant chemotherapy followed by surgery versus upfront surgery in patients with borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.
First Author: Junho Kang, MD


BOARD G11
Abstract 313: An updated retrospective review of the safety and efficacy of sorafenib for recurrent hepatocellular carcinoma post-liver transplantation.
First Author: Sophie Feng, MBBS


BOARD G12
Abstract 314: Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in first line metastatic pancreatic cancer (MPC): Updated results.
First Author: Vincent Picozzi, MD


BOARD G13
Abstract 315: Efficacy and safety of nivolumab in first-line or further treatment of advanced metastatic biliary tract cancer.
First Author: Miaomiao Gou


BOARD G14
Abstract 316: Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
First Author: Takuji Okusaka, MD


BOARD G15
Abstract 317: Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
First Author: Max Sung, MD


BOARD G16
Abstract 318: Neoadjuvant chemotherapy versus upfront resection in ampullary adenocarcinoma stratified by stage: A retrospective analysis using the National Cancer Database.
First Author: Shravan Leonard-Murali, MD


BOARD G17
Abstract 319: A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC).
First Author: Do-Youn Oh, MD, PhD


BOARD G18
Abstract 320: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).
First Author: Masatoshi Kudo, MD, PhD


BOARD G19
Abstract 321: Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
First Author: David Chan, MBBS


BOARD G20
Abstract 322: The role of perioperative systemic therapy in localized pancreatic neuroendocrine tumor.
First Author: Hao Xie, MD, PhD


BOARD H1
Abstract 323: Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.
First Author: Sadahisa Ogasawara, MD, PhD


BOARD H2
Abstract 324: Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer treated with gemcitabine and nab-paclitaxel.
First Author: Motoyasu Kan


BOARD H3
Abstract 325: Results from phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer.
First Author: Yusuke Hashimoto, MD


BOARD H4
Abstract 326: Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.
First Author: Richard Finn, MD


BOARD H5
Abstract 327: Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
First Author: Masatoshi Kudo, MD, PhD


BOARD H6
Abstract 328: External beam radiotherapy for hepatocellular carcinoma with right atrium tumor thrombus.
First Author: Danielle Bitterman, MD


BOARD H7
Abstract 329: Patterns of care and outcomes of definitive external beam radiotherapy and radioembolization for localized hepatocellular carcinoma: A propensity score-adjusted analysis.
First Author: Danielle Bitterman, MD


BOARD H8
Abstract 330: A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.
First Author: Uwe Pelzer, PhD


BOARD H9
Abstract 331: Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
First Author: Aaron Tan, MBBS, PhD, BSc


BOARD H10
Abstract 332: Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509).
First Author: Jaume Capdevila, MD


BOARD H11
Abstract 333: In vitro and in vivo efficacy of the combined treatment of 150 khz tumor treating fields (TTFields) and sorafenib in hepatocellular carcinoma.
First Author: Uri Weinberg, MD


BOARD H12
Abstract 334: Adjuvant chemotherapy with or without sequential radiation in resected pancreatic adenocarcinoma: Who will win RTOG 0848?
First Author: Ashwin Shinde, MD


BOARD H13
Abstract 335: Survival outcomes between surgery with adjuvant therapy compared to neoadjuvant therapy with surgery in stage I pancreatic adenocarcinoma: Results from a large national cancer database.
First Author: Samit Datta, MD


BOARD H14
Abstract 336: Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).
First Author: Charalampos Floudas, MD, DMSc, MS


BOARD H15
Abstract 337: Impact of glycemic control on treatment efficacy and safety during nabpaclitaxel plus gemcitabine therapy in unresectable pancreatic cancer.
First Author: Junko Tauchi


BOARD H17
Abstract 339: Safety and efficacy of high-intensity focused ultrasound in pancreatic cancer.
First Author: Jin Il Kim


BOARD H18
Abstract 340: Hepatocellular carcinoma and liver metastasis treated by hafnium oxide nanoparticles activated by SBRT: A phase I/II trial.
First Author: Enrique Chajon


BOARD H19
Abstract 341: Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.
First Author: Nicola Personeni, MD


BOARD H20
Abstract 342: Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).
First Author: Changhoon Yoo, MD


BOARD J1
Abstract 343: Effect of neoadjuvant chemoradiotherapy on prognosis in resectable and borderline resectable pancreatic cancer with venous involvement.
First Author: Minako Nagai, MD


BOARD J2
Abstract 344: Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean cancer study group (KCSG).
First Author: Changhoon Yoo, MD


BOARD J3
Abstract 345: Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.
First Author: Anne Demols, MD, PhD


BOARD J4
Abstract 346: Changes in alpha-fetoprotein (AFP) and systemic therapy outcomes in advanced hepatocellular carcinoma (HCC): A multicenter retrospective analysis.
First Author: Andrea Bocobo, BS


BOARD J6
Abstract 348: Risk factors of hepatic failure after liver resection for perihilar cholangiocarcinoma: Importance of future liver remnant volume, body weight ratio, and impact on long-term survival.
First Author: Jong Woo Lee, MD


BOARD J7
Abstract 349: The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113.
First Author: Ikuhiro Yamada, PhD, MD


BOARD J8
Abstract 350: Early stage hepatocellular carcinoma treated with stereotactic body radiation therapy: A pooled analysis from two North American institutions.
First Author: Ashwathy Mathew


BOARD J9
Abstract 351: Survival and cost associated with chemotherapy and chemoradiotherapy among resected pancreas cancer patients.
First Author: Nivethan Vela, MSc


BOARD J10
Abstract 352: Provider-volume associated with variable receipt of therapy and outcomes for noncurative pancreas adenocarcinoma: A population-based analysis.
First Author: Julie Hallet, MD


BOARD J11
Abstract 353: Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe.
First Author: Sharlene Gill, MD, MPH, MBA


BOARD J12
Abstract 354: Toxicity of FOLFOX-abraxane (FOLFOX-A) on phase II Brown University Oncology Group (BrUOG) trials.
First Author: Howard Safran, MD


BOARD J13
Abstract 355: Hepatic arterial infusion chemotherapy after sorafenib treatment in patients with advanced hepatocellular carcinoma who are unfit for regorafenib.
First Author: Takeshi Terashima, PhD


BOARD J14
Abstract 356: A multicenter cohort study of sunitinib (SU) versus imatinib (IM) dose escalation as second-line therapy in patients with gastrointestinal stromal tumors (GISTs) after disease progression of 400 mg/d IM.
First Author: Xinhua Zhang


BOARD J15
Abstract 357: Racial disparities in the receipt of adjuvant chemotherapy in patients with resected stage I-III pancreatic adenocarcinoma.
First Author: Nina Sanford, MD


BOARD J16
Abstract 358: Real world usage of gemcitabine and nabpaclitaxel in older adults with metastatic pancreatic cancer: A single institution experience.
First Author: Arthur Winer, MD


BOARD J17
Abstract 359: Update result of HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer.
First Author: Shintaro Nakano


BOARD J18
Abstract 360: Is rising BMI associated with an increased rate of clinically relevant pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma?
First Author: Evan Glazer, MD, PhD


BOARD K1
Abstract 361: Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients.
First Author: Thomas Yau


BOARD K2
Abstract 362: FOLFIRINOX in pancreatic cancer patients age 75 years or older.
First Author: Jonathan Mizrahi, MD


BOARD K3
Abstract 363: Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly-differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).
First Author: Claire Mulvey


BOARD K4
Abstract 364: A nationwide multicenter study in patients with unresectable hepatocellular carcinoma treated with lenvatinib in real world practice in Japan.
First Author: Kaoru Tsuchiya, MD, PhD


BOARD K5
Abstract 365: Randomised phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
First Author: Thomas Yau


BOARD K6
Abstract 366: Results of conversion surgery after the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic cancer.
First Author: Naoya Ikeda, MD


BOARD K7
Abstract 367: The effect of lymphocyte-to-monocyte ratio on efficacy of sorafenib for recurrent hepatocellular carcinoma after curative resection.
First Author: Hideki Yokoo, MD, PhD


BOARD K8
Abstract 368: The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113.
First Author: Makoto Ueno, MD


BOARD K9
Abstract 369: Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).
First Author: Efrat Dotan, MD


BOARD K10
Abstract 370: Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreas cancer.
First Author: Sara Zakem, MD


BOARD K11
Abstract 371: Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.
First Author: Angel Alsina, MD


BOARD K12
Abstract 372: Comparison of adjuvant chemotherapy, chemoradiation, and chemotherapy followed by chemoradiation for resected stage I-II pancreatic cancer.
First Author: Sung Jun Ma, MD


BOARD K13
Abstract 373: Prospective trial of functional liver image-guided hepatic therapy (FLIGHT) with hepatobiliary iminodiacetic acid (HIDA) scans and update of institutional experience.
First Author: David Long, MD


BOARD K14
Abstract 374: An analysis of the safety and efficacy of rivaroxaban (Riv) and low molecular weight heparin (LMWH) in gastrointestinal cancer-associated venous thromboembolism (GICA-VTE).
First Author: Alejandro Recio Boiles, MD


BOARD K15
Abstract 375: Outcome analysis of chemotherapy duration for resected stage I-II and unresected stage III pancreatic cancer.
First Author: Sung Jun Ma, MD


BOARD K16
Abstract 376: Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?
First Author: Rachel Lee, MD, MD, MSPH, MSPH


BOARD K17
Abstract 377: Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?
First Author: Adriana Gamboa, MD


BOARD K18
Abstract 378: Comparison of concurrent chemoradiation with stereotactic body radiation therapy versus conventionally fractionated radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer.
First Author: Sung Jun Ma, MD


BOARD K19
Abstract 379: Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors (NETs): A sequential case series.
First Author: Hagen Kennecke, MD


BOARD K20
Abstract 380: Differences in overall survival for patients with cholangiocarcinoma: Racial/ethnic disparity or socioeconomic factors?
First Author: Rachel Lee, MD, MD, MSPH, MSPH


BOARD L1
Abstract 381: Second-line chemotherapy in advanced biliary tract cancer: Who may benefit?
First Author: Massimiliano Salati, MD


BOARD L2
Abstract 382: Efficacy and tolerability of sorafenib in unresectable/advanced hepatocellular carcinoma patients: Real-life experience in a Hong Kong tertiary liver cancer institute.
First Author: Thomas Yau


BOARD L3
Abstract 383: Efficacy of liposomal-irinotecan (nal-IRI) plus 5-fluorouracil / folinic acid (5-FU/LV) versus oxaliplatin plus fluoropyrimidines in previous gemcitabine treated pancreatic adenocarcinoma (PAC) patients (pts).
First Author: Markus Kieler


BOARD L4
Abstract 384: Symptom burden of patients with advanced pancreas cancer (APC): A provincial cancer institute observational study.
First Author: Julie Ward


BOARD L5
Abstract 385: Gemcitabine, docetaxel, and capecitabine (GTX) as a first-line regimen in metastatic pancreatic adenocarcinomas (mPAC): A single institution experience.
First Author: Vikas Singh, MBBS


BOARD L6
Abstract 386: Combination of everolimus and lu-177 PRRT in treatment of G1-2 neuroendocrine tumors (NET): Phase 1-2 study.
First Author: Ali Aljubran, MD


BOARD L7
Abstract 387: Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
First Author: Tatsuya Ioka, MD


BOARD L8
Abstract 388: Pooled safety analysis of high-specific-activity I-131 MIBG in iobenguane scan positive cancer patients.
First Author: Camilo Jimenez


BOARD L9
Abstract 389: Combination chemotherapy for pancreatic cancer in older adults: Efficacy and safety analysis of patients at a majority-Hispanic NCI-designated cancer center.
First Author: Emily Henkel


BOARD L10
Abstract 390: Understanding practices and gaps in multidisciplinary hepatocellular carcinoma (HCC) care within the community oncology setting.
First Author: Lorna Lucas, MSM


BOARD L11
Abstract 391: A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma.
First Author: Aparna Parikh, MD, MS


BOARD L12
Abstract 392: Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.
First Author: Janet Murphy, MD


BOARD L13
Abstract 393: Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.
First Author: Sakti Chakrabarti, MD


BOARD L14
Abstract 394: Outcomes after cessation of therapy with alkylating agents (AA) for pancreatic neuroendocrine tumors (panNETs).
First Author: Y. Linda Wu, MD


BOARD L15
Abstract 395: The correlation between the proportion of patients with pancreatic ductal adenocarcinoma who received neoadjuvant therapy and overall survival between 2004 and 2015.
First Author: George Molina, MD, MPH


BOARD L16
Abstract 396: A network meta-analysis of adjuvant systemic therapy in resected pancreatic cancer.
First Author: Jorge Chaves Porras, MD


BOARD L17
Abstract 397: Impact of direct-acting antivirals and 12-week sustained viral response on clinical outcomes in patients with hepatitis c and hepatocellular carcinoma.
First Author: William Kamp


BOARD L18
Abstract 398: Incidence of and risk factors (RFs) for development of non-alcoholic fatty liver disease (NAFLD) after pancreaticoduodenectomy (PD) for pancreatic cancer: A single institutional review.
First Author: Amy McGhee-Jez, MD


BOARD L19
Abstract 399: Predictors of survival in pancreatic squamous cell carcinoma (PSCC): An analysis from the National Cancer Database (NCDB).
First Author: Anuhya Kommalapati


BOARD L20
Abstract 400: Treatment sequencing in MPC, insights from a 3˚ care center.
First Author: Ivan Barrera, MD


BOARD M1
Abstract 401: Outcomes of stereotactic body radiotherapy for unresectable hepatocellular carcinoma.
First Author: Yizhou Zhao, FRCPC, MD


BOARD M2
Abstract 402: Impact of adjuvant hepatic arterial chemoinfusion using high-dose 5-fluorouracil with systemic gemcitabine for pancreatic cancer: A propensity score–matched analysis.
First Author: Kota Nakamura, MD


BOARD M3
Abstract 403: Impact of new chemotherapy regimens on the treatment landscape and survival of advanced pancreatic cancer (PAC) patients (pts).
First Author: Markus Kieler


BOARD M4
Abstract 404: Plasma hyaluronan is a predictive marker for pegvorhyaluronidase alfa (PEGPH20; PVHA) response in a phase II study of pancreatic ductal adenocarcinoma (PDAC).
First Author: Darin Taverna, PhD


BOARD M5
Abstract 405: Oral chemotherapy as second-line treatment option for gemcitabine-refractory advanced pancreatic cancer with poor performance status.
First Author: Se Jun Park, M.D


BOARD M6
Abstract 406: Prognostic factors and disease course in patients enrolled onto clinical trials of second-line therapy for hepatocellular carcinoma.
First Author: Nicola Personeni, MD


BOARD M7
Abstract 407: Dynamical changes of treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice.
First Author: Kazuki Nagai, MD


BOARD M8
Abstract 408: Halo 110-101: Early safety results of pegvorhyaluronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC).
First Author: Do-Youn Oh, MD, PhD


BOARD M9
Abstract 409: Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer.
First Author: Taylor Maramara, MS


BOARD M10
Abstract 410: Neutrophil/lymphocyte ratio (NLR) may predict prognostic factor with gemcitabine, cisplatin (GC) for patients with advanced biliary tract cancer.
First Author: Toru Otsuru, MD


BOARD M11
Abstract 411: Effect of FOLFIRINOX with PEG-G-CSF for unresectable/recurrent pancreatic cancer.
First Author: Ichiro Moriyama


BOARD M12
Abstract 412: Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.
First Author: Alicia Smart


BOARD M13
Abstract 413: Clinical characteristics and predictors of outcomes in patients with fibrolamellar carcinoma: An eleven-year analysis of the National Cancer Database (NCDB).
First Author: Hussein Assi, MD


BOARD M14
Abstract 414: SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mfolfirinox versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.
First Author: Davendra Sohal, MD, MPH


BOARD M15
Abstract 415: Pathologic outcomes of systemic therapy followed by stereotactic body radiation therapy (SBRT) for pancreatic cancer (PC) in a novel lateral decubitus treatment position.
First Author: Ethan Song, BA


BOARD M16
Abstract 416: Prognostic factors associated with long term survival in chemotherapy-treated advanced pancreatic cancer: A Canadian multicenter analysis.
First Author: Christina Kim, MD


BOARD M17
Abstract 417: Impact of hospital volume and type on survival in hepatocellular carcinoma: Results from the National Cancer Database.
First Author: Johannes Uhlig


BOARD M18
Abstract 418: Outcomes following liver SBRT for metastatic pancreatic cancer.
First Author: Oluwadamilola Oladeru, MD, MA


BOARD M19
Abstract 419: The impact of histology (adenocarcinoma vs. SCC) on outcomes in nonmetastatic pancreatic cancer.
First Author: Joshua Gruhl, MD


BOARD M20
Abstract 420: A phase I/II study of RX-3117, an oral antimetabolite nucleoside, in combination with nab-paclitaxel (nab-pac) as first-line treatment of metastatic pancreatic cancer (met-PC): Preliminary results.
First Author: Hani Babiker, MD


BOARD N1
Abstract 421: Pulsed high-dose erlotinib with gemcitabine as second-line therapy for pancreatic adenocarcinoma.
First Author: Christopher Larson, MD, PhD


BOARD N2
Abstract 422: Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).
First Author: Andrea Fung, PhD, MD


BOARD N3
Abstract 423: Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
First Author: Robin Kelley, MD


BOARD N4
Abstract 424: Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the United States.
First Author: Neehar Parikh


BOARD N6
Abstract 426: Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio independently predict survival in resected small bowel adenocarcinoma.
First Author: Brandon Huffman, MD


BOARD N7
Abstract 427: Evaluation of disease-specific and functional symptom items on carcinoid tumor patients treated with telotristat ethyl.
First Author: Stacie Hudgens, MA, BA


BOARD N8
Abstract 428: Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion.
First Author: Pablo Munoz-Schuffenegger, MD


BOARD N9
Abstract 429: The need for improvement in the management of fatigue, depression and pain in pancreatic cancer.
First Author: Amy Westermann, MPH


BOARD N10
Abstract 430: Carcinoids of the ampulla: Long-term follow-up after endoscopic resection.
First Author: George Baison, MD


BOARD N11
Abstract 431: Phase I study of tramatinib combined with sorafenib in patients (pts) with advanced hepatocellular cancer (HCC).
First Author: Emilie Wang, MD


BOARD N12
Abstract 432: A retrospective study of hepatic arterial infusion (HAI) FUDR/Dex and mitomycin C (MMC) for chemotherapy refractory unresectable intrahepatic cholangiocarcinomas (ICC).
First Author: Gustavo Fernandes, MD


BOARD N13
Abstract 433: A new clinically based staging system for gallbladder cancer.
First Author: Siddhartha Yadav, MD, FACP


BOARD N14
Abstract 434: Phase II study of ibrutinib in advanced carcinoid and pancreatic neuroendocrine tumors.
First Author: Taymeyah Al-Toubah, MPH


BOARD N15
Abstract 435: Clinical outcomes of hepatocellular carcinoma variants compared to hepatocellular carcinoma.
First Author: Katerina Zakka, MD


BOARD N16
Abstract 436: Neoadjuvant therapy duration and outcome of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Safi Shahda, MD


BOARD N17
Abstract 437: Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT.
First Author: Michael Cecchini, MD


BOARD N18
Abstract 438: Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years.
First Author: Andrea Fung, PhD, MD


BOARD N19
Abstract 439: Undertreatment of noncurative pancreatic adenocarcinoma? A population-based analysis of patterns of care.
First Author: Michail Mavros


BOARD N20
Abstract 440: Comparison of radiation treatment volumes for borderline resectable pancreatic cancer.
First Author: Trevor Bluemel, BS, MD


BOARD P1
Abstract 441: Dosing modifications to increase tolerability of gemcitabine and nab-paclitaxel in treatment of pancreatic cancer in the elderly.
First Author: Jasmine Martin, MD


BOARD P2
Abstract 442: Neutrophil to lymphocyte ratio as a prognostic marker in patients with metastatic gallbladder cancer.
First Author: Mohamed Mady, M.B.Ch.B.


BOARD P3
Abstract 443: Combination therapy with TACE + ablation versus TACE + SBRT for hepatocellular carcinoma (HCC): Comparative analysis with propensity score-weighted cohorts.
First Author: Nima Nabavizadeh, MD


BOARD P4
Abstract 444: Impact of an inter-professional clinic on pancreatic cancer outcomes: The Princess Margaret Cancer Centre (PM) experience.
First Author: Hamzeh Albaba, MBBS


BOARD P5
Abstract 445: Rare subtypes of pancreatic cancer: Clinical outcomes and implications for clinical trial enrollment.
First Author: John David, MD


BOARD P6
Abstract 446: Resection of primary tumor in liver only metastatic midgut neuroendocrine tumors.
First Author: Nicholas Manguso


BOARD P7
Abstract 447: Local control following stereotactic body radiotherapy to adrenal oligometastases.
First Author: Nicholas Figura, MD


BOARD P8
Abstract 448: Comparison of neoadjuvant and adjuvant therapy for resectable pancreatic cancer using Markov decision modeling.
First Author: Minsig Choi, MD


BOARD P9
Abstract 449: Small bowel adenocarcinoma: A single center experience.
First Author: Lindsay Hannan, MD, MPH


BOARD P10
Abstract 450: Neoadjuvant therapy for body and tail pancreatic adenocarcinoma: Propensity score matched analysis using the National Cancer Database.
First Author: Tommy Ivanics, MD


BOARD P11
Abstract 451: FOLFIRI in advanced biliary tract cancers.
First Author: Jonathan Mizrahi, MD


BOARD P12
Abstract 452: Combined radiotherapy and transarterial chemoembolization as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion.
First Author: Sang MIN Yoon, MD, PhD


BOARD P13
Abstract 453: Impact of neoadjuvant radiation on survival in patients with pancreatic cancer undergoing neoadjuvant chemotherapy followed by pancreatectomy.
First Author: Francis Macedo, MD


BOARD P14
Abstract 454: Neoadjuvant multimodal treatment of borderline resectable (BRPC) and locally advanced unresectable pancreatic cancer (LAPC) in Mexico.
First Author: Vanessa Camargo, MD


BOARD P15
Abstract 455: Resection margin distance in extrahepatic cholangiocarcinoma: How much is enough?
First Author: Amir A. Rahnemai-Azar, M.D.


BOARD P16
Abstract 456: Retrospective, cohort study evaluating empiric dose-reduced nab-paclitaxel with gemcitabine in metastatic pancreatic adenocarcinoma: A single institution experience.
First Author: Olugbenga Olowokure, MBBS


BOARD P17
Abstract 457: Racial/ethnic disparities in the use of high-volume centers for hepatobiliary and pancreatic cancer surgery.
First Author: Susanna de Geus, MD pHD


BOARD P18
Abstract TPS459: GA CPI 613: A single arm, open-label phase I study of CPI-613 in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer.
First Author: Angela Alistar, MD


BOARD P19
Abstract TPS460: Precision-Panc Master Protocol: Personalizing treatment for pancreatic cancer ISRCTN14879538—Part of Precision-Panc United Kingdom.
First Author: Juan Valle, MD


BOARD P20
Abstract TPS461: Phase 2 trial of durvalumab and radiation revaccination in patients with metastatic adenocarcinoma of the pancreas who have progressed through first-line chemotherapy.
First Author: Michael Chuong, MD


BOARD Q1
Abstract TPS462: Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.
First Author: Tanios Bekaii-Saab, MD, FACP


BOARD Q2
Abstract TPS463: NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.
First Author: Tara Seery, MD


BOARD Q3
Abstract TPS464: Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).
First Author: Bridget Keenan, MD, PhD


BOARD Q4
Abstract TPS465: A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Andrea Wang-Gillam, MD, PhD


BOARD Q5
Abstract TPS466: Celiac plexus radiosurgery for pain management in advanced cancer patients: An international phase II trial.
First Author: Yaacov Lawrence, MA, MBBS, MRCP


BOARD Q6
Abstract TPS467: MORPHEUS: A Phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.
First Author: Jayesh Desai, FRACP


BOARD Q7
Abstract TPS468: FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.
First Author: Lipika Goyal, MD


BOARD Q8
Abstract TPS469: PANOVA-3: A phase III study of tumor treating fields with nabpaclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC).
First Author: Uri Weinberg, MD


BOARD Q9
Abstract TPS470: Phase II HEPANOVA trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma.
First Author: Anca Grosu, MD


BOARD Q10
Abstract TPS471: Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).
First Author: Pascal Hammel


BOARD Q11
Abstract TPS472: A phase Ib trial of anti-VEGFR/PDGFR vorolanib combined with immune checkpoint inhibitors (CPIs) in solid tumors.
First Author: Nusayba Bagegni, MD


BOARD Q12
Abstract TPS473: A randomized clinical trial of chemotherapy with gemcitabine/cisplatin/nabpaclitaxel with or without the AXL inhibitor bemcentinib (BGB324) for patients with advanced pancreatic cancer.
First Author: Muhammad Beg, MD, MS


BOARD Q13
Abstract TPS474: Adjuvant chemotherapy of S-1 versus S-1 plus metformin for resected pancreatic cancer: A multicenter-randomized-phase II trial.
First Author: Masato Narita, MD, PhD


BOARD Q14
Abstract TPS475: Phase II randomized, double-blind, study of mfolfirinox plus ramucirumab versus mfolfirinox plus placebo in advanced pancreatic cancer patients hcrn GI14-198.
First Author: Walid Shaib, MD


BOARD Q15
Abstract TPS476: A phase II, open-label pilot study evaluating the safety and activity of nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study).
First Author: Hiral Parekh, MD, MPH


BOARD Q16
Abstract TPS477: A phase II study of ADI-PEG 20 and FOLFOX6 in patients (pts) with advanced hepatocellular carcinoma (HCC).
First Author: James Harding, MD


BOARD Q17
Abstract TPS478: Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).
First Author: Kristen Spencer, DO


BOARD Q18
Abstract TPS479: Avenger 500, a phase III open-label randomized trial of the combination of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.
First Author: Philip Philip, MD, PhD, FRCP